The Federal Biomedical Agency (FMBA) has announced clinical trials of a new Russian vaccine against the Mir-19 coronavirus. The director of FMBA Veronika Skvortsova told about it. Her words are quoted by TASS.
Preclinical trials of the drug were completed in June.
“In preclinical studies, the safety, immunogenicity and protectiveness (protective potential) of the vaccine preparation have been proven. A package of documents has been prepared for obtaining permission to conduct clinical trials of the 1-3rd phases, which was submitted to the Ministry of Health at the end of June, ”Skvortsova said.
The second phase of clinical trials will be completed in August, and, if efficacy is confirmed, the drug will be registered. According to Skvortsova, the Mir-19 vaccine was developed on a new technological platform and is aimed at developing cellular immunity.
During the experiment, it was proved that the concentration of the virus in animals is reduced by 10 thousand times, and it was found that the effect of the vaccine is effective in the first 2-3 days after human infection. At the same time, the new drug does not affect the human genome and is relevant for different strains of coronavirus, including British and Indian.
Earlier, the epidemiologist of Rospotrebnadzor gave advice to the Russians who were left without antibodies to COVID-19 after vaccination. According to him, if after the introduction of two components of the vaccine, a person has zero antibody titers, after six months he should be vaccinated with another drug.
